Quantcast

Milan Study Presentation for Biogenics Research Chamber

June 24, 2013

Dr. Robert Jacobs, a Principal Investigator for the Biogenics Research Chamber, presented at the Congress of the European Academy of Allergy and Clinical Immunology and the World Allergy Organization in Milan, Italy on June 23, 2013

San Antonio, Texas (PRWEB) June 24, 2013

Dr. Robert Jacobs, a Principal Investigator for the Biogenics Research Chamber, presented at the Congress of the European Academy of Allergy and Clinical Immunology and the World Allergy Organization in Milan, Italy on June 23, 2013. The Congress is the world’s largest scientific meeting of allergists and immunologists. Dr. Jacobs discussed a San Antonio, Texas trial of rush immunotherapy for Virginia Live Oak allergy, with testing performed in the Biogenics pollen challenge chamber. Rush immunotherapy consists of giving allergy injections over a short time period to prevent the symptoms of allergy. Allergic symptoms affect as much as 20% of the population, with tree pollens being important seasonal offenders. Dr. Jacobs noted that oak pollen is a major cause of nasal and eye allergy symptoms during spring throughout much of the United States. The pollen challenge chamber provides consistent selected pollen exposure to a group of allergic participants involved in studies of therapies for allergic symptoms.

In addition to presenting the effects of rapid immunization on clinical symptoms, Dr. Jacobs discussed observed changes in tests of inflammation. The study is the first to utilize a pollen exposure chamber to measure the clinical and gene expression effects of rush immunotherapy.

About the Company:

Biogenics Research Chamber, located in San Antonio, Texas, is the only large permanent pollen exposure testing facility in the United States. Dr. Robert Jacobs, Dr. Daniel Ramirez and Dr. Charles Andrews are the owners and Principal Investigators. The facility has a large chamber capable of testing up to 60 allergic participants at a time and moderate sized chamber for testing up to 32 subjects. Both chambers utilize unique engineering and pollen delivery systems. Two additional chambers are being constructed. Compared to natural season allergy studies, the chambers offer controlled conditions without pollen concentration variation and weather interruptions. Proof of concept, dose-ranging, and onset of action studies are performed for pharmaceutical and vaccine trials. In addition to commercial studies, the Biogenics Research Chamber has performed multiple academic trials examining the basic mechanisms of allergy.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/6/prweb10833312.htm


Source: prweb



comments powered by Disqus